154 related articles for article (PubMed ID: 16985047)
1. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.
Voland C; Bord A; Péleraux A; Pénarier G; Carrière D; Galiègue S; Cvitkovic E; Jbilo O; Casellas P
Mol Cancer Ther; 2006 Sep; 5(9):2149-57. PubMed ID: 16985047
[TBL] [Abstract][Full Text] [Related]
2. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
3. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells.
Hata T; Yamamoto H; Ngan CY; Koi M; Takagi A; Damdinsuren B; Yasui M; Fujie Y; Matsuzaki T; Hemmi H; Xu X; Kitani K; Seki Y; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Mol Cancer Ther; 2005 Oct; 4(10):1585-94. PubMed ID: 16227409
[TBL] [Abstract][Full Text] [Related]
4. Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.
Vondálová Blanářová O; Jelínková I; Hyršlová Vaculová A; Sova P; Hofmanová J; Kozubík A
Cell Prolif; 2013 Dec; 46(6):665-76. PubMed ID: 24118195
[TBL] [Abstract][Full Text] [Related]
5. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.
Göschl S; Schreiber-Brynzak E; Pichler V; Cseh K; Heffeter P; Jungwirth U; Jakupec MA; Berger W; Keppler BK
Metallomics; 2017 Mar; 9(3):309-322. PubMed ID: 28205649
[TBL] [Abstract][Full Text] [Related]
7. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.
Meynard D; Le Morvan V; Bonnet J; Robert J
Oncol Rep; 2007 May; 17(5):1213-21. PubMed ID: 17390068
[TBL] [Abstract][Full Text] [Related]
10. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.
Lewis KA; Lilly KK; Reynolds EA; Sullivan WP; Kaufmann SH; Cliby WA
Mol Cancer Ther; 2009 Apr; 8(4):855-63. PubMed ID: 19372558
[TBL] [Abstract][Full Text] [Related]
11. Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.
Herůdková J; Paruch K; Khirsariya P; Souček K; Krkoška M; Vondálová Blanářová O; Sova P; Kozubík A; Hyršlová Vaculová A
Neoplasia; 2017 Oct; 19(10):830-841. PubMed ID: 28888100
[TBL] [Abstract][Full Text] [Related]
12. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.
Takahashi M; Koi M; Balaguer F; Boland CR; Goel A
J Biol Chem; 2011 Apr; 286(14):12157-65. PubMed ID: 21285347
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
14. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.
Montopoli M; Ragazzi E; Froldi G; Caparrotta L
Cell Prolif; 2009 Apr; 42(2):195-206. PubMed ID: 19236381
[TBL] [Abstract][Full Text] [Related]
15. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
16. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
17. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin.
Cruet-Hennequart S; Glynn MT; Murillo LS; Coyne S; Carty MP
DNA Repair (Amst); 2008 Apr; 7(4):582-96. PubMed ID: 18289945
[TBL] [Abstract][Full Text] [Related]
18. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N
Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
Lovejoy KS; Serova M; Bieche I; Emami S; D'Incalci M; Broggini M; Erba E; Gespach C; Cvitkovic E; Faivre S; Raymond E; Lippard SJ
Mol Cancer Ther; 2011 Sep; 10(9):1709-19. PubMed ID: 21750216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
